期刊文献+

阿立哌唑添加治疗缓解不全的抑郁症的开放性研究 被引量:1

Open study on Aripiprazole in treatment of incompletely-alleviated depression
下载PDF
导出
摘要 目的:初步探讨先前药物治疗仅部分有效的抑郁症患者添加阿立哌唑治疗后的有效性及安全性。方法:对35例诊断为抑郁症、先前SSRI或SNRI类或米氮平等药物治疗仅部份有效者添加阿立哌唑治疗,采用HAMD-17及不良反应量表在基线及疗后6周分别进行评定,并进行统计学处理。结果:添加阿立哌唑后HAMD-17量表分显著减少(P<0.05),并有约25%的患者获临床痊愈,且具有良好的耐受性。阿立哌唑的平均使用剂量为11.7mg/d。结论:添加阿立哌唑可有效治疗先前疗效不佳的抑郁症,阿立哌唑的平均剂量在11.7mg/d。 Objective To explore efficacy and safety of Aripiprazole adjunctive to antidepressant monotherapy in treatment ofincompletely-alleviated depression. Methods: 35 patients, diagnosed as depression and partly alleviated by former SSRIs or SNRIs orMirtazapine treatment, were selected and treated with Aripiprazole additionally. 6 weeks after the treatment, HAMD-17 and TESSwere used to evaluate the efficacy. The statistical treatment was performed. Results: A significant reduction in HAMD-17 scores wasobserved (P〈0. 05) and 25% of the patients had been remitted after addition of Aripiprazole. Aripiprazole had a good tolerance andthe mean dose was 11. 7mg/ d. Conclusions: In the patients who fail to respond to initial antidepressant therapy, adjunctive Aripi-prazole is more effective and its mean dose is 11. 7mg/ d.
机构地区 苏州市广济医院
出处 《中国民康医学》 2014年第24期27-28,32,共3页 Medical Journal of Chinese People’s Health
关键词 阿立哌唑 抑郁症 Aripiprazole Depression
  • 相关文献

参考文献6

  • 1Crown WH, Finkelstein S, Bemdt ER, et al. The impact of treat-ment-resistant depression on health care utilization and costs[J].J Clin Psychiatry, 2002,63:963-971.
  • 2Fava M. Diagnosis and definition of treatment-resistant depression[J]. Boil psychiatry, 2003, 53:649-659.
  • 3Ward MP, Irazoqui PP. Evolving refractory major depressive disor-der diagnostic and treatment paradigms: toward closed-loop thera-peutics[J]. Front Neuroeng,2010,3:7.
  • 4Patkar A, Peindl K, Mago R, et al. An open-label, rater-blin-ded, augmentation study of aripirazole in treatment-resistant de-pression[J]. Prim care companion J Clin Psychiatry,2006,8(2):82-87.
  • 5宋红梅,吴延海,骆祥芬,吴维.阿立哌唑对难治性抑郁症的增效作用观察[J].蚌埠医学院学报,2012,37(3):286-287. 被引量:7
  • 6王春雁,倪珂,李东旭,李磊.盐酸文拉法辛缓释片合并阿立哌唑治疗难治性抑郁症的对照分析[J].精神医学杂志,2012,25(5):374-375. 被引量:16

二级参考文献13

  • 1于宏伟.西酞普兰与文拉法辛治疗抑郁症对照研究[J].临床精神医学杂志,2006,16(1):36-37. 被引量:13
  • 2沈渔邮.精神病学[M].北京:人民出版社,2002:100-102.
  • 3田国强,梁胜林,秦国兴.文拉法辛缓释剂治疗难治性抑郁症的疗效观察[J].浙江临床医学,2007,9(8):1057-1057. 被引量:12
  • 4Sackeim HA. The definition and meaning of treatment-resis - tant depression [ J]. J Clin Psychiatry,2001,62(suppl) :10 - 17.
  • 5Barbee JG, conrad E J, Jamhour NJ. The effectiveness of olanzapine, risperidone quetiapine, and ziprasidone as augmentation agents in treatment - resistant major depressive disorder [ J]. J clin psychiatry,2004,65:975 - 981.
  • 6Marcus RN, McQuade RD, Carson WH, et al. Efficacy and safety of aripipazole as adjunctive therapy in major depressive disorder [ J ]. J clin Psychopharmacology,2008,28 : 156 - 165.
  • 7Barbee JG, Conrad El, Jamhour NJ. Aripiprazole augmentation in treatment - resistant depression [ J ]. Ann Clin Psychiatry, 2004,16:189 - 194.
  • 8Worthington JJ, Kinrys G, Wyqant IE, et al. Aripiprazole as an angmentor of selective serotonin rcuptake inhibitors in depression and anxiety disorder patients [ J ]. Int clin Psychopharmacol,2005 ,20 :9 - 11.
  • 9Bardin L, Auclair A, Kleven Ms, et al. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/semtonin 5-HTIA activity : comparison with typical and atypical conventional antipsychotics [ J ]. Behav Pharmacol, 2007,18:103 - 118.
  • 10饶冬萍,唐牟尼,徐贵云.难治性抑郁症的研究进展[J].国际精神病学杂志,2008,35(1):13-16. 被引量:47

共引文献21

同被引文献3

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部